NCT00457782View on ClinicalTrials.gov

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

January 31, 2011

Conditions
Multiple MyelomaChronic Lymphocytic LeukaemiaB-cell Non-Hodgkin's Lymphoma
Interventions
DRUG

KW-2478

Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts

Trial Locations (6)

Unknown

St Bartholomew's Hospital, London

UCLH, London

Christie Hospital, Manchester

Nottingham University NHS Trust, Nottingham

Cancer Research UK Clinical Centre, Southampton

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
collaborator

Kyowa Hakko Kirin UK, Ltd.

INDUSTRY

lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT00457782 - A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter